UK Defence Journal

UK paratroopers join multinational Exercise Falcon Leap

Seventy-seven British Army paratroopers from 16 Air Assault Brigade took part in Exercise Falcon Leap 2025 in the Netherlands, supported by Royal Air Force transport aircraft and instructors, the UK ...
IEEE

An efficient No-Line-of-Sight learning approach for Prediction of Static Victim Detection Using Genetic Algorithm and Kth Nearest Neighbor Data Classification

Abstract: In emergencies, among the most effective methods for saving lives is spotting and locating victims. While time is against them, quick actions are essential for victims. The first 48 hours, ...
IEEE

Static Line Rating of Overhead Power Lines in Various European Countries

Abstract: This article compares the static line rating (SLR) values defined for overhead power lines in various European countries. The results reveal significant variations in SLR values between ...
Hosted on MSN

U.S. Marines fly aboard U.K. A400 aircraft to Norwegian Island

U.S. Marines with Force Reconnaissance Platoon, Maritime Raid Force, 31st Marine Expeditionary Force, conduct static line jumps and freefall jumps from an MV-22B Osprey assigned to Marine Medium ...
BioSpace

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer

Based on DESTINY-Breast09 Phase III trial results which showed ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP with a median progression-free survival of ...
Monthly Prescribing Reference

Trastuzumab Deruxtecan + Pertuzumab Under Review For First-Line HER2+ Metastatic Breast Cancer

A regulatory decision is expected during the first quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...
BioSpace

ENHERTU® Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer

Based on DESTINY-Breast09 phase 3 trial results, which showed ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival of ...